Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: A phase II trial (CALGB 8944) Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Breast Neoplasms

abstract

  • After multimodality treatment for locally advanced breast cancer, long-term survival was correlated with the number of pathologically positive lymph nodes, but not to clinical response. The hazard of death was highest during the first 5 years after diagnosis and declined thereafter, indicating a possible intermediate endpoint for future trials of neoadjuvant treatment.

publication date

  • February 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4217205

Digital Object Identifier (DOI)

  • 10.1007/s10549-008-9943-2

PubMed ID

  • 18306034

Additional Document Info

start page

  • 479

end page

  • 90

volume

  • 113

number

  • 3